Articles with public access mandates - Axel GrotheyLearn more
Not available anywhere: 6
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...
The Lancet Oncology 22 (6), 779-789, 2021
Mandates: AIRC Foundation for Cancer Research in Italy
Influence of KRAS and BRAF mutational status and rash on disease-free survival (DFS) in patients with resected stage III colon cancer receiving cetuximab (Cmab): Results from …
SR Alberts, SN Thibodeau, DJ Sargent, MR Mahoney, F Sinicrope, ...
Journal of Clinical Oncology 29 (15_suppl), 3607-3607, 2011
Mandates: US National Institutes of Health
Pilot experience with adjuvant FOLFIRI with or without cetuximab in patients with resected stage III colon cancer: NCCTG Intergroup N0147.
J Huang, DJ Sargent, MR Mahoney, AF Shields, E Chan, RM Goldberg, ...
Journal of Clinical Oncology 29 (15_suppl), 3522-3522, 2011
Mandates: US National Institutes of Health
Reply to SA Kesikli et al
J Franko, D Sargent, A Grothey
Journal of Clinical Oncology 30 (18), 2288-2289, 2012
Mandates: US National Institutes of Health
Reply to M. Mandalà et al
J Franko, HC Pitot, A Grothey
Journal of Clinical Oncology 30 (15), 1895-1895, 2012
Mandates: US National Institutes of Health
Reply to A. Chan et al
A Grothey, CL Loprinzi, J Sloan
Journal of Clinical Oncology 29 (16), e490-e491, 2011
Mandates: US National Institutes of Health
Available somewhere: 116
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
Mandates: Cancer Research UK, National Institute for Health Research, UK
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
Mandates: US National Institutes of Health, Fonds de recherche du Québec - Santé
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer
DJ Sargent, S Marsoni, G Monges, SN Thibodeau, R Labianca, ...
Journal of clinical oncology 28 (20), 3219-3226, 2010
Mandates: US National Institutes of Health
Chemotherapy for advanced gastric cancer
AD Wagner, NLX Syn, M Moehler, W Grothe, WP Yong, BC Tai, J Ho, ...
Cochrane database of systematic reviews, 2017
Mandates: Federal Ministry of Education and Research, Germany
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy
S Kopetz, GJ Chang, MJ Overman, C Eng, DJ Sargent, DW Larson, ...
Journal of clinical oncology 27 (22), 3677-3683, 2009
Mandates: US National Institutes of Health
Duration of adjuvant chemotherapy for stage III colon cancer
A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ...
New England Journal of Medicine 378 (13), 1177-1188, 2018
Mandates: US National Institutes of Health, Cancer Research UK, UK Medical Research …
NCCN guidelines insights: colon cancer, version 2.2018
AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ...
Journal of the National Comprehensive Cancer Network 16 (4), 359-369, 2018
Mandates: US National Institutes of Health
Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology
AB Benson, AP Venook, MM Al-Hawary, L Cederquist, YJ Chen, ...
Journal of the National Comprehensive Cancer Network 16 (7), 874-901, 2018
Mandates: US National Institutes of Health
A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID‐19) pandemic: an international collaborative group
HO Al‐Shamsi, W Alhazzani, A Alhuraiji, EA Coomes, RF Chemaly, ...
The oncologist 25 (6), e936-e945, 2020
Mandates: National Medical Research Council, Singapore
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials
D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ...
Journal of Clinical Oncology 27 (6), 872-877, 2009
Mandates: US National Institutes of Health
Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis
Y Wang, S Zhou, F Yang, X Qi, X Wang, X Guan, C Shen, N Duma, ...
JAMA oncology 5 (7), 1008-1019, 2019
Mandates: US National Institutes of Health
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841
J Franko, Q Shi, CD Goldman, BA Pockaj, GD Nelson, RM Goldberg, ...
Journal of Clinical Oncology 30 (3), 263-267, 2012
Mandates: US National Institutes of Health
Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial
SR Alberts, DJ Sargent, S Nair, MR Mahoney, M Mooney, SN Thibodeau, ...
Jama 307 (13), 1383-1393, 2012
Mandates: US National Institutes of Health
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the …
J Franko, Q Shi, JP Meyers, TS Maughan, RA Adams, MT Seymour, ...
The Lancet Oncology 17 (12), 1709-1719, 2016
Mandates: Cancer Research UK
Publication and funding information is determined automatically by a computer program